Difference between revisions of "Oprelvekin (Neumega)"
Jump to navigation
Jump to search
m |
m |
||
| Line 10: | Line 10: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Subcutaneous medications]] | ||
| + | |||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
[[Category:FDA approved in 1997]] | [[Category:FDA approved in 1997]] | ||
Revision as of 23:25, 23 February 2021
Mechanism of action
Synthetic version of IL-11, a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.
History of changes in FDA indication
- 11/25/1997: Initial FDA approval (no label available on Drugs @ FDA)
- 9/18/2002: Label "indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia."
Also known as
- Brand name: Neumega